Effect of beinaglutide,a thrice-daily GLP-1 receptor agonist,on body weight and metabolic parameters:A systematic review and metaanalysis  

作　　者：Abul Bashar Mohammad Kamrul-Hasan Vanishri Ganakumar Lakshmi Nagendra Deep Dutta M Rafiqul Islam Joseph M Pappachan 

机构地区：[1]Department of Endocrinology,Mymensingh Medical College,Mymensingh 2200,Bangladesh [2]Department of Endocrinology,Jawaharlal Nehru Medical College,Belagavi 590010,Karnataka,India [3]Department of Endocrinology,JSS Medical College,JSS Academy of Higher Education and Research,Mysore 570015,Karnataka,India [4]Department of Endocrinology,CEDAR Superspeciality Healthcare,New Delhi 110075,Delhi,India [5]Department of Internal Medicine,Shaheed Suhrawardy Medical College Hospital,Dhaka 1207,Bangladesh [6]Faculty of Science,Manchester Metropolitan University,Manchester M156BH,United Kingdom [7]Department of Endocrinology,Kasturba Medical College,Manipal Academy of Higher Education,Manipal 576104,India

出　　处：《World Journal of Diabetes》2025年第5期374-387,共14页世界糖尿病杂志(英文)

摘　　要：BACKGROUND Beinaglutide,a short-acting glucagon-like polypeptide-1 receptor agonist,has shown variable efficacy in weight reduction and metabolic control in randomized controlled trials(RCTs).AIM To summarize the therapeutic effects of beinaglutide in patients with overweight/obesity with/without type 2 diabetes.METHODS RCTs involving patients receiving beinaglutide in the intervention arm and placebo or active comparator in the control arm were searched through multiple electronic databases.The change from baseline in body weight was the primary outcome;secondary outcomes included changes in body mass index(BMI),waist circumference(WC),blood pressure,glycemic parameters,lipids,and adverse events(AEs).RevMan web was used to conduct meta-analysis using random-effects models.Outcomes were presented as mean differences(MDs),odds ratios(ORs),or risk ratios(RRs)with 95%confidence intervals(95%CIs).RESULTS Six RCTs(n=800)with mostly some concerns about the risk of bias were included.Over 12-24 weeks,beinaglutide 0.1-0.2 mg thrice daily was superior to the control group in reducing total(MD=-3.25 kg,95%CI:-4.52 to-1.98,I^(2)=84%,P<0.00001)and percent(MD=-4.13%,95%CI:-4.87 to-3.39,I^(2)=54%,P<0.00001)body weight reduction.Beinaglutide also outperformed the control group in achieving weight loss by 5%(OR 4.61)and 10%(OR=5.34).The superiority of beinaglutide vs the control group was also found in reducing BMI(MD=-1.22 kg/m^(2),95%CI:-1.67 to-0.77)and WC(MD=-2.47 cm,95%CI:-3.74 to-1.19]).Beinaglutide and the control group had comparable impacts on blood pressure,glycemic parameters,insulin resistance,hepatic transaminases,and lipid profile.Beinaglutide posed higher risks of treatment discontinuation due to AEs(RR=3.15),nausea(RR=4.51),vomiting(RR=8.19),palpitation(RR=3.95),headache(RR=2.87),and dizziness(RR=6.07)than the control.However,the two groups had identical risks of total and serious AEs,diarrhea,fatigue,and hypoglycemia.CONCLUSION Short-term data from RCTs suggested that beinaglutide causes modest benefits in reduc

关 键 词：Beinaglutide Glucagon-like polypeptide-1 receptor agonist OBESITY Type 2 diabetes Weight reduction Metaanalysis 

分 类 号：R58[医药卫生—内分泌]